申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利

Core Viewpoint - The company Shenyuan Biotech (688098.SH) announced that its affiliate Yangzhou Shizhi Source Biotechnology Co., Ltd. has received a patent from the National Intellectual Property Administration for a novel treatment method for HIV infection using monoclonal antibodies targeting CD4 [1] Group 1: Patent and Technology - The patent pertains to a method for treating and functionally curing HIV infection through monoclonal antibodies that target CD4, including their compositions and usage [1] - The drug UB-421, under development by Shizhi Source, has a unique mechanism of action that effectively blocks HIV from entering host cells by competitively binding to the CD4 receptor on T cells [1] Group 2: Market Implications - UB-421 is expected to have a lower probability of inducing viral resistance mutations compared to existing HIV treatments, as it does not directly target viral genes [1] - The drug will primarily focus on areas such as multi-drug resistance and functional cure in the domestic market [1]